N-Hydroxy-7-[4-(N-morpholinyl)benzoyl]heptanamide | 362670-88-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-Hydroxy-7-[4-(N-morpholinyl)benzoyl]heptanamide
• 英文别名: N-hydroxy-8-(4-morpholin-4-ylphenyl)-8-oxooctanamide
• CAS: 362670-88-0
• 化学式: C₁₈H₂₆N₂O₄
• 分子量: 334.415
• InChiKey: LKFRVSVMJDPBJI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  24
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  78.9
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Inhibitors of histone deacetylase
  申请人：——

  公开号：US20020115826A1

  公开（公告）日：2002-08-22

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及组蛋白去乙酰化酶的抑制。本发明提供了用于抑制组蛋白去乙酰化酶酶活性的化合物和方法。本发明还提供了用于治疗细胞增殖性疾病和状况的组合物和方法。
• Inhibitors of Histone Deacetylase
  申请人：Delorme Daniel

  公开号：US20090181971A1

  公开（公告）日：2009-07-16

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及抑制组蛋白去乙酰化酶的技术。本发明提供了抑制组蛋白去乙酰化酶酶活性的化合物和方法。本发明还提供了治疗细胞增殖性疾病和病状的组合物和方法。
• INHIBITORS OF HISTONE DEACETYLASE
  申请人：Methylgene, Inc.

  公开号：EP1280764A2

  公开（公告）日：2003-02-05
• METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR
  申请人：Yu Qiang

  公开号：US20110053882A1

  公开（公告）日：2011-03-03

  The invention relates to a method of preventing, inhibiting, arresting or reversing tumourigenesis in a cell as well as a method of inducing apoptosis in a tumour cell. The method includes increasing the amount and/or the activity of a DACT protein, or a functional fragment thereof, in the cell. Also provided is a pharmaceutical composition that comprises a compound of general formula (I), wherein A is CH or N, R 1 , R 4 and R 5 are independent from each other H, an aliphatic group, an alicyclic group, an aromatic group, an arylaliphatic group, and an arylalicyclic group comprising 0-3 heteroatoms. The heteroatoms may be N, O, S, or Si. R 4 and R 5 may optionally be linked so as to define an aliphatic hydrocarbyl bridge. R 2 is H or a halogen such as F, Cl, Br or L. R 3 is H, F, Cl or an aliphatic or arylaliphatic group that includes 1-8 main chain carbon atoms and 0-3 heteroatoms. The pharmaceutical composition also comprises a histone deacetylase inhibitor.
• US7288567B2
  申请人：——

  公开号：US7288567B2

  公开（公告）日：2007-10-30